EU Authorized Representative for Medical Devices and IVDs in Europe
For non-EU manufacturers, bringing medical devices or in vitro diagnostic devices into the European market involves more than product quality, technical documentation and regulatory preparation. Before a device can be placed on the European market, the manufacturer must appoint an EU Authorized Representative based within the European Union and formally recognised as the manufacturer’s authorised representative. This role is essential under the Medical Device Regulation and the In Vitro Diagnostic Medical Device Regulation because regulators need a responsible local party who can communicate, provide documentation and support compliance activities when required. An eu-authorized-representative is far more than just a name printed on a label. They serve as the legal presence of a non-EU manufacturer and play a vital role in ensuring market access, regulatory trust and ongoing post-market accountability.
Why an EU Authorized Representative Is Required
European regulations for medical devices aim to safeguard patients, healthcare providers and users by ensuring every product entering the market has a defined chain of responsibility. When a manufacturer is based outside the European Union, regulators cannot always deal with that manufacturer directly in the same practical way they would with a local company. This is exactly where the EU Authorized Representative becomes essential. The representative provides a formal local presence and serves as the official point of communication for Competent Authorities, Notified Bodies and other regulatory stakeholders.
Without designating an authorised representative, a non-EU manufacturer is not permitted to place medical devices or IVDs on the European market. This requirement applies across a broad spectrum of products, from low-risk devices to advanced diagnostic technologies. The requirement exists before market entry, which means the representative must be appointed early in the compliance process rather than treated as a final administrative step. For manufacturers planning European distribution, choosing the right EU Authorized Representative for Medical Devices and IVDs can directly affect registration readiness, documentation control and long-term regulatory stability.
The Written Mandate Between Manufacturer and Representative
The connection between the manufacturer and the EU Authorized Representative must be formalised through a written mandate. This mandate defines the tasks the representative is authorised to perform and confirms the obligations both parties must follow. It is a critical compliance record as it defines the scope of representation, responsibilities, communication roles and the actions required if compliance issues occur.
An unclear or weakly drafted mandate can cause uncertainty at critical moments, particularly during authority requests, inspections, complaint handling or corrective actions. A strong mandate should clearly describe how documents will be made available, how regulatory communication will be handled, how incident information will be shared and what happens if the manufacturer does not meet its duties. For this reason, the mandate should be prepared carefully and reviewed before device registration or market placement begins.
Label and Packaging Requirements
The name and address of the EU Authorized Representative must be displayed on the device label, packaging or associated product information in accordance with applicable regulations. This allows authorities, distributors, healthcare professionals and users to identify the local representative linked to the device. It also reinforces the representative’s role as the official European presence for a manufacturer located outside the European Union.
Labelling accuracy matters because incorrect or missing representative information can create compliance concerns and may delay market access. Manufacturers should ensure that their artwork, instructions, declarations and registration information are aligned before products are released. If the representative is changed, labelling and registration details may also require timely and controlled updates.
Documentation Review and Availability
A key responsibility of an EU Authorized Representative for Medical Devices and IVDs is to ensure that essential compliance documents are available and correctly prepared. This involves confirming the existence of the EU Declaration of Conformity, ensuring technical documentation is complete and verifying that the appropriate conformity assessment route has been followed based on device type and risk classification.
The representative may also be required to retain or access copies of technical files, declarations and Notified Body certificates. These documents must be available for inspection by Competent Authorities for the required retention period after the last device has been placed on the market. This places document control at the core of the manufacturer–representative relationship. Manufacturers should maintain updated records and ensure that the representative can respond quickly if regulators request information.
Communication With Competent Authorities and Notified Bodies
The EU Authorized Representative serves as the formal communication link between the non-EU manufacturer and European regulatory authorities. If a Competent Authority requests information, samples, technical documentation or clarification, the representative is expected to support the response process. The representative may also communicate with Notified Bodies when required, especially where certificates, conformity assessment or corrective actions are involved.
This communication role eu-authorized-representative requires more than forwarding messages. A dependable representative should understand regulatory requirements, maintain accurate records and ensure responses are delivered within required timelines. Delayed or incomplete responses can create serious issues for manufacturers, including market restrictions or further regulatory review. For this reason, manufacturers should work with a representative who has strong regulatory knowledge and clear internal processes.
Post-Market Surveillance and Incident Support
Compliance for medical devices does not stop once the product reaches the market. Once a device is in use, manufacturers must continue monitoring performance, complaints, incidents and safety signals. The EU Authorized Representative has a role in supporting this post-market responsibility by passing complaints and incident information to the manufacturer without delay.
This is particularly critical when information originates from clinicians, patients, users, distributors or authorities. Timely communication helps the manufacturer assess whether further investigation, reporting, field safety action or corrective action is needed. An effective representative recognises that post-market surveillance goes beyond documentation. It is part of patient safety, product improvement and ongoing regulatory trust.
Registration Responsibilities and EUDAMED
Within European regulatory frameworks, manufacturer and representative details must be registered as necessary. The EU Authorized Representative may support the registration of both the manufacturer and representative information in EUDAMED. Accurate registration helps authorities identify responsible parties, review device information and maintain market oversight.
Manufacturers should gather complete company information, device details, certificates and declarations before starting registration. Any mismatch between labelling, declarations, technical documentation and registration records may lead to delays or compliance concerns. The representative’s role helps ensure all required information is aligned and accessible when required.
When the Representative Must Take Action
An EU Authorized Representative also carries responsibilities if the manufacturer does not fulfil regulatory requirements. If serious non-compliance occurs and the manufacturer does not correct the issue, the representative may need to end the mandate and inform relevant authorities and the Notified Body where applicable. This responsibility shows why the role is more than administrative.
The representative holds legal responsibility and cannot overlook serious compliance breaches. Manufacturers should therefore treat the representative as a regulatory partner rather than a passive service provider. Open communication, timely document updates and clear responsibility sharing help prevent misunderstandings and reduce risk during the product life cycle.
Choosing the Right EU Authorized Representative
Selecting an EU Authorized Representative should be done with care. Manufacturers should look for regulatory competence, experience with medical devices and IVDs, document handling capability, clear response procedures and a strong understanding of European requirements. The representative should be able to support communication with authorities, maintain records and guide the manufacturer on practical compliance expectations.
Cost alone should not determine the choice. A weak representative can create delays, poor communication and unnecessary risk, while a capable representative can help maintain confidence throughout market entry and post-market activities. The correct selection provides non-EU manufacturers with a reliable European presence and enables smoother regulatory management.
Conclusion
An EU Authorized Representative is a mandatory requirement for non-EU manufacturers aiming to introduce medical devices or IVDs into the European market. The role covers legal representation, document availability, regulatory communication, complaint management, registration assistance and intervention in cases of serious non-compliance. Under the Medical Device Regulation and In Vitro Diagnostic Medical Device Regulation, appointing an authorised representative is not optional and should be completed before market placement begins. By selecting a capable EU Authorized Representative for Medical Devices and IVDs, manufacturers can enhance compliance, protect patient safety and establish a solid foundation for long-term European market access.